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Abstract
Background: In the last decade many studies showed that the exhaled breath of subjects suffering from several
pathological conditions has a peculiar volatile organic compound (VOC) profile. The objective of the present work
was to analyse the VOCs in alveolar air to build a diagnostic tool able to identify the presence of pancreatic ductal
adenocarcinoma in patients with histologically confirmed disease.
Methods: The concentration of 92 compounds was measured in the end-tidal breath of 65 cases and 102 controls.
VOCs were measured with an ion-molecule reaction mass spectrometry. To distinguish between subjects with
pancreatic adenocarcinomas and controls, an iterated Least Absolute Shrinkage and Selection Operator multivariate
Logistic Regression model was elaborated.
Results: The final predictive model, based on 10 VOCs, significantly and independently associated with the
outcome had a sensitivity and specificity of 100 and 84% respectively, and an area under the ROC curve of 0.99. For
further validation, the model was run on 50 other subjects: 24 cases and 26 controls; 23 patients with histological
diagnosis of pancreatic adenocarcinomas and 25 controls were correctly identified by the model.
Conclusions: Pancreatic cancer is able to alter the concentration of some molecules in the blood and hence of
VOCs in the alveolar air in equilibrium. The detection and statistical rendering of alveolar VOC composition can be
useful for the clinical diagnostic approach of pancreatic neoplasms with excellent sensitivity and specificity.
Keywords: Alveolar air, Volatile organic compounds, Pancreatic adenocarcinoma, IMR-MS, LASSO logistic regression
Background
The use of exhaled air in clinical practice had acquired
significant prominence by the end of the 80s, when this
biological material started to be used for the diagnostics of
poisoning from volatile substances [1] or for the biological
monitoring of professional exposures to solvents [2, 3].
In 1985 for the first time the possibility of identifying
the presence of lung cancer through the examination of
exhaled air [4] was pointed out. In subsequent phases
Phillips et al. [5] made an analogous research using less
complex equipment and confirmed the possibility of rec-
ognizing the presence of lung neoplasms using alveolar
air. The same group of Authors stated that they had
been able to observe 3481 different volatile organic com-
pounds (VOCs) in exhaled air. Among them, 1753 had a
positive alveolar gradient which suggests a prevalent en-
dogenous or metabolic origin. The other 1728 had a
negative alveolar gradient suggesting a prevailingly ex-
ogenous origin [6].
The same team published some results concerning pa-
tients with breast cancer [7]. Additionally, they broad-
ened and deepened the analysis on lung neoplasms [8].
Theoretically, every important biological variation of
the organism should come with significant biochemical
changes and with interferences to the functionality of
the immune defence system.
In fact, some modifications in the profile of the prod-
ucts present in the exhaled air were recorded in various
clinical conditions: hepatic steatosis [9] active
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tuberculosis [10] schizophrenia [11], heart transplant
[12] and cystic fibrosis [13, 14].
Some changes in the profile of the products exhaled have
been observed in pregnant women affected by preeclamp-
sia compared to those with a normal pregnancy [15].
The possibility of identifying subjects affected by dif-
ferent kinds of neoplasms requires the use of various
analytic methods with very different characteristics.
Mazzone et al. [16] prepared a “colorimetric sensor
array” which by examining the exhaled air of patients af-
fected by lung neoplasm, permits us to distinguish pa-
tients from controls with considerable sensitivity and
specificity. Some types of “artificial odour sensors”
allowed Taivans et al. [17] to distinguish patients with
various lung pathologies (bronchial asthma and chronic
obstructive pulmonary disease) including lung neo-
plasms, from control subjects. Peng et al. [18] used gold
nanoparticle sensors to analyse the VOCs in the exhaled
air of patients affected by lung cancers, or rectal colon,
or prostate disorders, to separate them from control
subjects. Using a “proton transfer reaction mass spec-
trometry”, Bajtarevic et al. [19] were able to detect some
revealing differences in the quality of the exhaled air of
subjects affected by lung cancer if compared to control
subjects.
In this multifaceted frame of researches, we analysed
the alveolar air in a group of patients affected by pancre-
atic ductal adenocarcinoma (PDA) cytohistologically
confirmed and in a group of control subjects using an
ion molecule reaction mass spectrometry (IMR-MS).
The method we applied for the analysis of the alveolar
air samples has been used just in few studies, but with
good results [9, 20]; nevertheless it is frequently used for
the analysis of environmental pollutants. In our opinion
this method provides very interesting data in particular
if they are associated to an appropriated statistical elab-
oration. The goal of the present study was to examine
whether each profile of the analysed VOCs could permit
us to identify an algorithm discriminating the two
groups of subjects, able to become a novel safe, not inva-
sive and easy method to diagnose PDA.
Methods
Subjects
In this study the cases enrolled were subjects admitted
to the Pancreatic Unit of the Surgical Department at
the Verona University Hospital between 2008 and 2013.
The inclusion criteria were the cytohistological diagno-
sis of PDA, and age higher than 18 years. For each
patient we collected: personal and medical history,
smoking patterns, alcohol consumption, oncologic
marker CA19-9, and the report of the final cytological
or histological exam. The diagnosis of pancreatic ductal
adenocarcinoma (PDA) is not easy and certainly
difficult at an early stage. Sometime the PDA is found
during routine health checks and is not accompanied
by any clinical symptoms. Sometime some clinical
symptoms such jaundice or intestinal disorders require
thorough diagnostic tests which lead to the diagnosis of
PDA. Often only histological results allow a sure diag-
nosis. We involved patients with diagnosis of PDA and
planned to undergo surgery without any recent chemo-
therapy in order to verify possible changes in the com-
position of the alveolar air; the neoplasm was therefore
not in a too advanced stage, but in some cases not in
the early stage neither. Patients involved in this study
were planned for the surgical intervention and alveolar
air samples were collected 1-3 days before surgery in
order to avoid any interference with VOCs in alveolar
air related to drugs used in the operating room or to
the stress related of surgical intervention. Controls
were recruited during hospital medical inspections. It is
difficult to identify “perfectly healthy control subjects”
and with the same age as patients with pancreatic neo-
plasm; we selected people hospitalized and submitted
to some clinical tests that did not detect any neoplasm
or other important diseases. Many control subjects
were hospitalized patients planned for slight surgical
interventions such venous or hemorrhoidal varices, in-
guinal hernias etc. Other control subjects were outpa-
tients selected among people periodically checked for
slight respiratory disorders (e.g., non-allergic rhinitis,
mild bronchial asthma) hypertension or psychological
disorders but in good general health conditions. More-
over, even the same pathologies were also recorded in
several patients with pancreatic cancer. Subjects with
previously diagnosed neoplasms, or with significant
pathologies, such as multiple sclerosis or other patholo-
gies of the central nervous system, were excluded from
the control group. Patients provide their alveolar sam-
ples in the morning, fasted, to avoid the possible inter-
ferences of food or its metabolites on the VOCs profile.
Also controls gave their alveolar air samples always in
the morning, fasted or more than 2 h away from meals
(for outpatients). All subjects involved provided written
consent to their participation in the research.
In a second phase, to validate the predictive model, we
analysed breath samples on a further group of fifty sub-
jects, 24 of them with PDA and 26 as controls: the same
inclusion criteria above described (age: between 40 and
75 years) were adopted: alveolar air samples were col-
lected 1-3 days before surgery in patients with PDA his-
tologically confirmed. Control subjects were selected
among outpatients periodically checked for moderate re-
spiratory disorders or for work related psychological dis-
orders, not affected by any neoplasm and in good
general health conditions. Their alveolar air samples
were collected in the morning 2 h away from meals.
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Sampling of alveolar air
Subjects were asked to make one deep exhalation inside
a hand-device called Bio-VOC breath sampler® (Markes
International Ltd., Rhondda Cynon Taff, UK), which is
in essence a special 250 ml air syringe; it has got a valve
in order to avoid any re-breathing phase by the subject,
especially at the end of the blow, and the exhaled air
follows a one way path. It was originally designed for air
sampling discharged into sorbent tubes or for direct
discharge on read out instruments.
While the subject was exhalating into the Bio-Voc
breath sampler, a test tube, or vial was put at the other
side of the sampler, to collect the exhaled air. The vial is
described as a 20 ml glass tube with wide bordered
opening, formerly sterilized and kept at 80 °C for at least
24 h, to avoid presence of environmental pollutants. The
whole exhalation was channelled into the test tube, in
order to further “clean” from possible environmental
VOC. At the end of the exhalation, the vial (now con-
taining the last part of the exhaled air, the alveolar air)
was closed with a Teflon septum (PTFE) and hermetic-
ally sealed with an aluminium ring. A sample of environ-
mental air in the same room was also taken into a 20 ml
vial: air in the vial was drawn with a 100 ml manual
pump to allow environmental air to fill it. In this case
too, the vial was closed and sealed.
The test tubes were kept at − 20 °C until the analysis.
The quality of the collection of the alveolar air was eval-
uated by the concentration of CO2 registered in the ana-
lysis: samples with less than 2% CO2 were considered as
incorrectly collected, and were excluded from the statis-
tical analysis.
Equipment
The analysis of the VOCs was performed by using the
AirSense analyser and the V&F-auto sampler (V&F med-
ical development GmbH, Absam, Austria) as described
by Hornuss et al. [20] and Netzer et al. [9]. This equip-
ment uses a combination of two integrated Mass spec-
trometer (MS) systems consisting of a conventional MS
capable of fast CO2 tracing controlling a second, highly
sensitive MS for measuring the VOCs [21]. The AirSense
consists of a highly sensitive MS with a soft ionization
unit. The ionization of sample gas is performed through
soft ionization by charge exchange between a primary
ion (e. g. Xe+; 12,1 eV) and the molecule to be analysed.
Primary ions are produced by electron impact in a
closed ion source. This technology allows interference-
free detection of molecules, which would not be possible
by means of standard ionization techniques with ener-
getically fast electrons (at least 70 eV) due to fragmenta-
tion and ionization (mass identity). The primary ions are
focused by high frequency fields in an octopole separator
and guided to the charge exchange cell. Through mass
separation, contamination of the spectrum from source
gases, as well as O2 and N2, is avoided and thus the
sensibility of the system rises considerably. In the charge
exchange, cell ions meet the sample gas which is ionized
through charge exchange reactions (Ion Molecule Reac-
tion). Here too, ions are focused by high frequency fields
and led to the actual high resolution mass filter.
Each alveolar air sample is transferred to the mass
spectrometer through the V&F-auto sampler which
maintains the biological sample at 65 °C for 60 min be-
fore the transfer. In few seconds the concentration of
several VOCs in the alveolar air sample is obtained.
The calibration of the mass spectrometer was per-
formed by using various calibration mixtures containing
CO2 and O2 at 10 and 5% respectively (from Messer Ita-
lia spa, Settimo Torinese, Italy). The measured gas com-
pounds were given as absolute concentrations (ppb) and
volume percent for CO2 and O2. Twelve other products
were directly calibrated: methanol, acetonitrile (ACN),
ethanol, methyl ethyl ketone (MEK), acetone, isoprene,
n-propanol, benzene, toluene, n-heptane, ammonia
(NH3) and sulphur dioxide (SO2). Other VOCs were
indirectly calibrated to the sensitivity of one directly
calibrated component (benzene) and named with “M”
followed by the molecular weight of compounds de-
tected. This nomenclature is maintained in the following
paper’s text and in figures and tables too.
This concept represents a semi quantitative calibration
procedure that is widely used in (multicomponent) ana-
lytical devices.
Statistics
Considering the large number of independent variables in-
volved in the analysis, we decided to base the elaboration
of the predictive model on a LASSO (Least Absolute
Shrinkage and Selection Operator) logistic regression (LLR)
[22, 23]. The LASSO is a penalized estimation method
which avoids overfitting, caused by to collinearity or high-
dimensionality of independent variables, through the
shrinking of the estimated regression coefficients. A tuning
parameter λ controls the amount of shrinkage applied to
the estimates. The shrinkage of some coefficients to zero
reduces the number of covariates in the final model.
A 50-fold cross-validation was applied to all steps of
the LLR, and independent variables (molecules) were
standardized to allow optimal penalization.
In detail, we adopted a slightly modified version of
the iterated LLR as described by Huang and colleagues
[24]. First, we used an LLR to reduce the number of
variables in the model, eliminating all variables if coeffi-
cients were 0 and ignoring their coefficients if these
were > 0. Second, we included the remaining variables
in a two-steps iterated LLR [24]: a first LLR to generate
penalized weights to be used in an adaptive LLR [25].
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Penalized weights were calculated as inverse logistic re-
gression coefficients. For this last regression, confi-
dence intervals of the regression coefficients were
calculated with a 10-fold iterated Bootstrap procedure.
Descriptive analyses were carried out with Stata/IC 11.
2 (StataCorp LP, College Station, TX, USA). Logistic
regressions were carried out with R version 2.15.1 (The
R Foundation for Statistical Computing, Vienna, Austria)
and R packages “penalized” (Goeman JJ. Penalized R
package, version 0.9-42) and “polywog” (Kenkel B,
Signorino CS. Bootstrapped Basis Regression with
Oracle Model Selection, version 0.2-0).
Results
In this study we enrolled 219 subjects (mean age
52 years, range 21-83) who signed an informed consent
form. Among them, 144 were controls (mean age 47,
range 21-78) and 75 were patients suffering from PDA
(mean age 62, range 23-83).
All subjects were able to carry out the air sampling
without difficulties, after a quick and easy explanation.
Out of the 75 patients with PDA, we recorded positivity
for the marker Ca19.9 in 49 patients.
In order to homogenize ages between cases and con-
trols, however, we restricted the sample to cases and
controls with ages ≥40 and ≤ 75. We, thus, excluded one
23 year old patient with ductal adenocarcinoma, 41 con-
trols of < 40 years of age, one 78 year old control and 9
cases of ductal adenocarcinoma with > 75 years of age. A
description of the restricted sample of 167 subjects (102
controls, 65 cases with ductal adenocarcinoma,) is pre-
sented in Table 1. We found no significant difference in
terms of sex distribution between controls and the out-
come group. Despite the age restriction, however, a sig-
nificant difference was found between age of controls
and age of patients suffering from PDA.
In Table 2 we report some descriptive parameters that
summarize the results of the measurement for the
VOCs, for which we prepared a scaling curve, in samples
of both environmental air and alveolar air of control
subjects. The concentration ranges (in ppb) found in the
international literature confirm that our results are
reliable and comparable with those registered by other
authors, both for the environmental concentration and
for alveolar one [21, 26–31]. Moreover, indoor air con-
centration of SO2 and NH3 are similar to those found by
Leaderer et al. [32] and Salem et al. [33].
Figure 1 shows the profile of the products detected
in the alveolar air of studied subjects (unbroken line)
and in the environmental air (dotted line) in the con-
sulting room where the patients and the control sub-
jects were received. The concentration of the each
molecule (in ppb) with specific molecular weight rep-
resents the median of 219 samples. The x-axis of the
figure shows the series of the molecular weights of
the analysed products. Data are shown after the deletion
of the group of molecules with a significantly greater
environment concentration, compared to the alveolar
concentration: these molecules, partially absorbed by the
human organism, are found in the alveolar air just in pro-
portion to the amount kept at a pulmonary level. A higher
alveolar concentration compared to the environmental
one, suggests a biological-metabolic origin. Besides, the
appearance of these molecules in the alveolar air is the ex-
pression of their partial positive pressure in the blood,
compared to the environmental air, suggesting a tendency
of the organism to eliminate them through the exhaled air.
They are 70 molecules, among which are: acetone, aceto-
nitrile, n-heptane, isoprene, MEK, NH3, SO2, toluene and
benzene, for which we had prepared a specific calibration.
The first LLR was run with age, sex and all 70 VOCs.
From the 50-fold cross-validation procedure we obtained
a λ value of 1.867425. Applying this λ we obtained a
model with 21 VOCs plus age: all other variables (49
VOCs and sex) had regression coefficients equal to zero
and were thus discarded. The second LLR (LASSO
followed by an Adaptive LASSO), which included age
and the remaining 21 VOCs, produced a model based
on age plus 10 VOCs (Table 3). This final model has an
area under the ROC curve of 0.9879 (Fig. 2). This model
is able to identify all cases (sensitivity = 100%) with only
16 false positives out of 102 (specificity = 84.3%).
Table 1 Alveolar air and pancreatic neoplasms: description of
the sample of cases and controls of ages ≥40 and ≤ 75, n.167*
Controls (n.102) Ductal Adenocarcinomas (n.65)
Gender
- males 51 (50%) 36 (55%)
- females 51 (50%) 29 (45%)
Age
- mean (SD) 53 (9) 61 (8)
- median (IQR) 51 (45-61) 61 (55-68)**
Preexisting or previous diseases
Arterial hypertension 12 10
diabetes mellitus 6 13
Other previous and
resolved neoplasms
3 11
other pancreatic
diseases
2 //
other pathologies 11 6
SD standard deviation, IQR inter-quartile range
*Differences between controls and outcome categories were calculated
with Fisher exact test for dichotomous independent variables and with
non-parametric Mann-Whitney rank sum test for continuous variables not
distributed normally. Only significant differences (p < 0.05) are reported in
the table
**Mann-Whitney: p = 0.000
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Otherwise, with a sensitivity of 95.4% (3/65 false nega-
tives), specificity reaches 92.2% (8/102 false positives).
Table 4 reports the main statistical parameters of al-
veolar concentrations (expressed in ppb) of ten VOCs
selected by the final model both for cancer patients and
controls. Some VOCs have concentrations round a few
ppb, but some others overtake thousands of ppb. In pa-
tients affected by PDA the median concentrations of
Ammonia, M43, M71, M74, M89 and M112 are higher
than in controls, while those of M34, M44, M62, Sulfur
dioxide are lower.
For an additional validation of the model we collected
other alveolar air samples from new 50 subjects 40-
75 years-old: 24 patients were admitted into our surgical
department with histologically identified ductal
adenocarcinoma and 26 were controls. Methods for VOC
collection and their measurements were the same used for
the other subjects. Table 5 reports the main statistical pa-
rameters of alveolar concentrations (expressed in ppb) of
the ten VOCs selected by the model both for further new
patients with PDA and controls. By using the same cut-off
previously calculated, the model correctly classified 23
cases of 24, meaning a sensitivity of 95.8% and 25 controls
of 26 with a specificity of 96.2%.
Discussion
The most relevant results of our study are:
i) In presence of PDA the normal VOCs profile in the
exhaled air changes
Table 2 Environmental and alveolar concentration of products for which we prepared a specific calibration. Data are expressed in
ppb and regard 219 samplings both for environmental and alveolar concentrations
Enviromental Concentration Alveolar Concentration
Mean Median range 5-95th percentile Mean Median range 5-95th percentile
Methanol 654 633 267-1789 323-1166 537 492 259-3021 294-841
Acetonitrile 196 129 34-1820 48-802 269 176 43-1840 66-1164
Ethanol 924 525 71-6244 121-3187 532 349 47-8668 88-1361
MEK 55 45 12-352 14-147 102 78 20-622 36-281
Acetone 217 181 52-2432 67-392 721 534 116-10,179 244-1676
Isoprene 20.8 18 5-262 8.9-34.4 160 149 17-428 63-292
n-Propanol 79 47 16-2093 20-172 98 80 31-619 45-194
Benzene 6.1 5.6 0.1-21 0.7-13 11.7 9.4 0.9-85.7 2.2-35.9
Toluene 5.2 4.8 0.1-22.1 1.1-11.7 5.8 4.8 0.6-25.9 1.6-14.5
n-Heptane 19.5 14.3 4.6-679.5 6.7-34.1 18.7 15.6 4.1-500.1 6-31.5
SO2 10.3 10.4 4.3-25.7 5.9-14.6 5.9 9.8 3.1-16.7 4.5-13.8
NH3 77 70 17-302 24-116 118 101 14-737 40-246
Fig. 1 Alveolar (unbroken line) and environmental (dotted line) concentrations used for the statistics (70 groups of molecules): molecules which were
significantly more present in the environmental air than in the alveolar air have been excluded (data are reported in ppb). The 22 molecules excluded
were the following: M19, M26, M27, M28, M31, M32, M45, M48, M49, M73, M92, M97, M98, M102, M103, M104, M105, M116, M117, M18, M120 and M121
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ii) The profile of the VOCs has the potential to become
a test to discriminate between subjects with ductal
adenocarcinoma and subjects without the disease.
The adenocarcinoma of the pancreas is the most com-
mon pancreatic tumour (around 95%) and the fourth
most common cause of death due to cancer in the USA
It often has an unfavourable prognosis: considering all
stages, the survival is respectively 25% at one year and
6% at 5 years [34]. Nevertheless the only possibility of
treatment is the removal of small tumours formerly dis-
covered [35].
Research for an early diagnosis is therefore a priority
of extraordinary relevance. Unfortunately, at present the
results have not been satisfactory [36], even though sev-
eral approaches have been tried [37]. Serum CA19-9
represents the “gold standard” marker to verify the pres-
ence of a pancreatic cancer. The diagnostic sensitivity of
the CA19-9 is 79% (70-90%), its specificity is 82% (68-
91%), with a positive predictive value of 72% (41-95%)
and the negative predictive value of 81% (65-98%) [38].
In addition, 10-15% of the people do not produce the
CA19-9 because of the Lewis-negative genotype [39].
Besides, the serum levels of this indicator are high even
in other benign and malignant pathologies [40].
Concerning 10 molecules we detected as important for
the ductal Adenocarcinoma model only 5 are known:
two of these are quantified and calibrated by IMR-MS in
our equipment conditions; they are ammonia (M17) and
sulphur dioxide (M64). Three compounds with MW
34 Da (Da), 43 and 44 Da, considering the electronic
charge-discharge conditions of our instrument are
hydrogen sulphide, acetyl group and acetaldehyde re-
spectively. For the last five masses of ten, we did not find
in the literature any report associating them to products
already found by other Authors in the alveolar air sam-
ples of patients with any kind of cancer. Their chemical
identification is not possible with the method we used
and must be provided by other techniques (i.e. GC-MS,
which however needs preconcentration of the sample).
Table 3 Ductal Adenocarcinoma Model obtained from the first and second LASSO logistic regression (n = 167)
Variables Regression Coefficients of the first LLRa Regression Coefficients of the second LLRb 95% CIb
Intercept −5.3255467964 −4.832765 −19.837 – + 4.153
Age + 0.1493804071 + 0.119876 + 0.032 – + 0.403
Ammonia + 0.0036286701 + 0.001723 + 0.000 – + 0.023
M34 −0.1699431526 − 0.102787 − 0.402 – + 0.000
M37 + 0.0006675672 // //
M42 + 0.0009076002 // //
M43 + 0.0007153015 + 0.002183 −0.006 – + 0.005
M44 + 0.0047526254 + 0.001295 + 0.001 – + 0.051
M46 −0.0007407600 // //
M60 −0.0003390278 // //
Propanol + 0.0054942415 // //
M62 −0.2138505207 −0.335321 −1.007 – − 0.077
Sulfur dioxide − 0.2595054348 −0.384319 − 1.116 – − 0.132
M66 − 0.1459224298 // //
M71 + 0.0062530914 + 0.012486 + 0.000 – + 0.040
M74 −0.0120892660 −0.021012 − 0.159 – + 0.000
M75 − 0.0008072235 // //
M88 −0.0142597155 // //
M89 + 0.2297944263 + 0.426043 + 0.536 – + 2.368
M91 −0.0286331109 // //
M106 −0.0135291587 // //
M111 + 0.0926572905 // //
M112 + 0.0054448431 + 0.023171 + 0.000 – + 0.230
CI confidence interval, obtained from a 10-fold iteration Bootstrap procedure
aRegression Coefficients of the first LASSO logistic regression (2nd column)
bRegression coefficients of the Ductal Adenocarcinoma Model obtained from the second, iterated LASSO logistic regression (3rd and 4th columns)
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In order to better characterize these five unknown
masses, we considered all the molecules with weights 62,
71, 74, 89 and 112 Da, reported by PubChem (http://
pubchem.ncbi.nlm.nih.gov), or by the ChemSpider free-
on-line database from the Royal Society of Chemistry
(http://RSC.org; http://www.chemspider.com).
Among the matched molecules we excluded:
 Molecules of clear industrial or environmental origin
(for example products containing chlorine atoms or
fluorine, bromine, etc.);
 Molecules with ester linkage (as they are easily
ionisable in the blood and they cannot be expelled
with the alveolar air);
 Highly reactive molecules, which show instability in
the biological matrix (i.e. free radicals);
 Molecules with a boiling point above 150 °C, with a
high steam pressure (above 20 mm/Hg at 25 °C) and
with a low enthalpy of vaporisation (> 20 KJoule/mol):
their concentration in the alveolar air should be so
low that we cannot detect them with our equipment.
Next we illustrate the compounds with the mentioned
MW and which corresponded to the criteria above re-
ported: only ethylphosphane (CAS 593-68-0), had the
right inclusion criteria for compounds with MW 62 Da.
Among the products with MW of 71 Da, the possible
presence in the alveolar air concerned the Formyl cyan-
ate (CAS 471-47-0) and the 1,2,3,4-Oxatriazole. (Chem-
Spider ID: 10609508).
The majority of the compounds with MW of 74 Da
had a boiling point above 150 °C, and just four satis-
fied the other criteria reported: methallylamine
[EINECS 220-724-2], N-ethylethanimine (CAS 1190-
79-0), N-ethylethenamine (ChemSpider ID: 9415459),
2,3-Dimethylaziridine (ChemSpider ID: 10295849).
Three compounds with MW of 89 Da showed the
required parameters: 1-nitropropane (CAS 108-03-2),
2-nitropropane (CAS 79-46-9) and 2-(Dimethyl
Fig. 2 Sensitivity and specificity curves for the Ductal
Adenocarcinoma Model and Receiver Operating Characteristic curve
(area under ROC = 0.9879)
Table 4 Main statistical parameters related to VOCs selected by the final predictive model to discriminate between 65 subjects with
pancreatic ductal adenocarcinoma (PDA) and 102 controls (data in ppb)
Ammonia M34 M43 M44 M62 Sulfur dioxide M71 M74 M89 M112
Control subjects
Median 91.0 19.4 1025.7 7220.3 7.3 11.0 31.9 7.9 1.3 8.9
Geometrical Mean 88.8 18.7 1023.9 6576.8 7.5 10.4 36.1 9.4 1.5 9.6
Minimum value 13.8 9.4 288.8 2879.3 2.3 4.9 12.5 2.2 0.1 2.8
Maximum value 459.6 29.5 2697.8 14,011.8 41.7 14.5 186.9 383.5 15.2 152.6
Arithmetic mean 106.5 19.2 1087.5 6918.8 8.7 10.6 44.5 17.4 2.2 12.0
Standard deviation 72.9 4.0 397.8 2115.9 5.7 2.0 36.1 41.7 2.5 15.4
Patients with PDA
Median 106.7 12.4 1195.7 6106.7 5.7 6.0 42.2 8.4 3.5 14.0
Geometrical Mean 118.2 12.8 1337.8 6141.6 6.3 6.9 41.2 9.6 3.4 14.5
Minimum value 33.4 8.5 402.4 3521.3 1.9 3.1 15.4 1.9 0.3 6.1
Maximum value 737.0 30.4 13,697.7 10,436.8 33.1 16.7 179.1 130.9 42.1 71.4
Arithmetic mean 136.7 13.3 1874.4 6371.2 7.7 7.7 49.4 16.2 5.7 16.7
Standard deviation 102.8 4.4 2109.5 1749.0 6.0 3.6 34.5 22.5 6.9 10.9
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amino)ethanol (CAS 108-01-0). Many molecules with
MW of 112 Da are of artificial origin; among those
which satisfy our inclusion criteria we find 2,3-Diamino-
1,3-butadiene-1,4-dione (ChemSpider ID: 17269477) and
1,1-diisocyanatoethane (ChemSpider ID: 10122761).
Further studies will be necessary to find out which mole-
cules, among those we have pointed out (even if not-
named), could be considered the most specific and useful
markers in the detection of the pancreatic adenocarcinoma.
With the involvement of new cases of pancreatic neo-
plasm we ran the model for the validation test that
didn’t confirm the same sensitivity, nevertheless the re-
sults were good.
The predictive model reaches 100% sensitivity and a
good specificity which can be recalibrated, for clinical or
epidemiological studies in order to have higher specifi-
city values with an acceptable sensitivity. Other require-
ments for a good analysis, met by this method, are:
speed, security, minimal invasiveness and low costs. In-
deed, it is a very quick test. After a short explanation
about the importance of a deep inhalation, the sample
can be obtained in the time of an exhalation.
Certainly, in “preliminary performance studies” such as
this one, each attempt to identify illness indicators can
prove vain. Since it could point out some altered elements
in a productive phase, it cannot be used in an early phase
[41]. The appearance of clinical manifestations in this kind
of tumour can be both early and late, depending on the re-
gion of the pancreas concerned. Therefore, it is not pos-
sible at the first hospitalization to speak of neoplasm as
being at the early stages or as being very advanced. The
evolution of the pancreatic cancer and the inadequate cur-
rently available instruments for early diagnosis in this field
persuaded us to study it through the analysis of the alveo-
lar air. Oxidative stress is a possible causal factor for pan-
creatic cancer [42, 43] and is hypothetically able to alter
the concentration of volatile compound exhaled. At
present, our intuition is that in some way it is not the sub-
stances taken one by one that are so important for the de-
tection of the pancreatic cancer, but the “movement” of a
group of different molecules that determines the prediction
of pathology. To the best of our knowledge, this is the first
study which addresses the possibility of identifying patients
suffering from PDA by the VOC profile of alveolar air.
Conclusions
Predictive models, based on VOCs profiles in alveolar air,
obtained from the use of high precision instruments and
advanced statistical methods, could contribute to the diag-
nosis of such a cryptic kind of neoplasm with high sensi-
tivity and specificity. We reach 100% sensitivity with a
specificity of 84%. The analysis of alveolar air, in view of
the first results achieved, is undoubtedly a very promising
test for detection of pancreatic ductal adenocarcinoma.
The integration of VOCs profiles and blood specific
markers could further improve the detection of different
kind of neoplasms and other pathologies.
Additional file
Additional file 1: Environmental and alveolar concentrations of
measured volatile organic compounds. The file contains all raw data
about environmental (sheet 1) and alveolar (sheet 2) concentrations of
measured products with the sample codes and the main parameters (sex,
age and case-control classification) of enrolled subjects. Red printed VOCs
were directly calibrated for the mass spectrometer analysis. (XLSX 417 kb)
Table 5 Main statistical parameters related to VOCs related to the 50 subjects (26 controls and 24 cases) used for validation of the
model itself
Ammonia M34 M43 M44 M62 Sulfur dioxide M71 M74 M89 M112
Control subjects
Median 101.5 17.7 849.5 5430.4 5.1 10.8 17.5 8.0 1.3 6.9
Geometrical Mean 101.0 18.6 873.9 5400.7 4.7 11.0 19.4 9.4 1.4 8.0
Minimum value 27.3 14.9 622.0 3755.8 2.1 9.0 12.4 4.5 0.1 5.1
Maximum value 359.1 24.2 1430.9 7560.7 11.0 14.8 46.0 106.9 14.1 73.5
Arithmetic mean 123.6 18.8 888.5 5513.7 5.1 11.0 20.5 13.7 1.9 10.1
Standard deviation 85.4 2.4 176.2 1134.5 2.2 1.1 7.9 20.1 2.6 13.1
Patients with PDA
Median 185.7 9.8 1319.2 3154.1 11.3 6.3 21.6 31.0 5.1 19.5
Geometrical Mean 205.6 6.1 1518.1 2477.8 10.5 7.0 22.8 29.6 4.6 21.8
Minimum value 52.7 0.9 581.3 461.9 3.0 5.1 15.8 6.9 1.2 8.8
Maximum value 1193.3 18.5 5377.7 4964.1 29.7 38.7 38.0 302.7 11.4 58.2
Arithmetic mean 293.7 8.4 1811.5 2881.4 12.2 7.9 23.7 45.0 5.3 25.9
Standard deviation 293.7 5.0 1213.8 1337.4 6.8 6.6 6.7 60.9 2.9 15.7
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